AJANTPHARM - Swing Trade Analysis with AI Signals

Last Updated Time : 19 Sept 25, 2:15 pm

Swing Trade Rating: 3.2

📊 Technical & Momentum Analysis

Price vs DMA: Trading below both 50-DMA (₹2,609) and 200-DMA (₹2,644), indicating short-term weakness and lack of bullish confirmation.

RSI (44.0): Neutral-to-weak zone—no momentum signal, but not oversold either.

MACD (-21.8): Bearish crossover—momentum is fading.

Volume: Slightly below 1-week average, suggesting low conviction and lack of breakout strength.

📈 Fundamental Snapshot

Metric Value Interpretation

P/E 34.0 Fairly valued vs industry PE (33.4)

PEG Ratio 4.29 Overpriced relative to growth—valuation caution

ROCE / ROE 33.0% / 25.7% Excellent capital efficiency—supports long-term quality

Debt-to-Equity 0.01 Virtually debt-free—financially robust

PAT Growth (QoQ) +32.1% Strong earnings momentum—positive sentiment driver

FII/DII Change Flat / +0.02% Minimal institutional movement—neutral impact

🧠 Swing Trade Logic

Bias: Fundamentally strong but technically weak setup.

Catalyst: Strong ROCE/ROE and PAT growth, but no momentum confirmation.

Risk: Weak RSI and MACD, plus low volume—entry should be delayed until reversal signals appear.

🎯 Optimal Entry Price

Buy Zone: ₹2,520–₹2,540

(Near short-term support with stop-loss below ₹2,480)

🚪 Exit Strategy

If Already Holding

Target Exit: ₹2,620–₹2,660 (Resistance near 50-DMA and prior swing zone)

Stop-Loss: ₹2,480 (Below MACD base and recent support)

Selva, this setup is best treated as a watchlist candidate until momentum confirms. If you're building a pharma basket, I can scan for peers with better PEG alignment and breakout overlays. Let’s refine that layer when you're ready.

Edit in a page